FindTrial
Sign In

A single center, Randomized controlled, opened clinical reserch for evaluating the effectiveness of recombinant human thrombopoietin combined with immunosuppressive therapy in the treatment of newly diagnosed acquired severe aplastic anemia

A single center, Randomized controlled, opened clinical reserch for evaluating the effectiveness of recombinant human thrombopoietin combined with immunosuppressive therapy in the treatment of newly diagnosed acquired severe aplastic anemia

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-14005720
Enrollment
Unknown
Registered
2014-12-17
Start date
2015-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe aplastic anemia

Interventions

TPO:rTPO
Ciclosporine:Ciclosporine

Sponsors

Blood Diseases Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. age 18~75 years old; 2. ECOG score 0~2; 3. newly diagnosed SAA; 4. be not eligible for HSCT, and willing for treatment with ATG+CSA; 5. without severe organ damage; 6. sign informed consent.

Exclusion criteria

Exclusion criteria: 1. congenital bone marrow failur; 2. clonal abnomality; 3. uncontroled infection; 4. severe heart, kidney, liver disease; 5. other tumor; 6. in breast feeding or pregnacy period; 7. history of thrombosis.

Design outcomes

Primary

MeasureTime frame
blood routine;bone marrow exmination;blood biochemistry;—

Countries

China

Contacts

Public ContactZhang Fengkui
zhfk@hotmail.com+86 022 23909229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026